Published in Cancer Weekly, September 17th, 2002
Martin Bornhauser and colleagues at Carl Gustav Carus University in Dresden assessed the benefits and risks of unrelated, CD34-selected peripheral blood progenitor cell (PBPC) grafts for leukemia and lymphoma patients.
The researchers found that these grafts were associated with high rates of infection and other complications and that donor lymphocyte infusions (DLI) offers limited protection against these developments.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.